Literature DB >> 29390925

Diagnostic criteria and contributors to Gilbert's syndrome.

Karl-Heinz Wagner1, Ryan G Shiels2, Claudia Anna Lang1, Nazlisadat Seyed Khoei1, Andrew C Bulmer2.   

Abstract

Hyperbilirubinemia is a well-known condition in the clinical setting; however, the causes of elevated serum bilirubin are diverse, as are the clinical ramifications of this condition. For example, diagnoses of individuals vary depending on whether they exhibit an unconjugated or conjugated hyperbilirubinemia. Diagnoses can include conditions of disordered bilirubin metabolism (Gilbert's, Crigler-Najjar, Rotor, or Dubin-Johnson syndromes) or an acquired disease, including alcoholic/non-alcoholic fatty liver disease, hepatotropic hepatitis, cirrhosis, or hepato-biliary malignancy. Assessment of bilirubin concentrations is typically conducted as part of routine liver function testing. Mildly elevated total bilirubin with normal serum activities of liver transaminases, biliary damage markers, and red blood cell counts, however, may indicate the presence of Gilbert's syndrome (GS), a benign condition that is present in ∼5-10% of the population. In this case, mildly elevated unconjugated bilirubin in GS is strongly associated with "reduced" prevalence of chronic diseases, particularly cardiovascular diseases (CVD) and type 2 diabetes mellitus (and associated risk factors), as well as CVD-related and all-cause mortality. These reports challenge the dogma that bilirubin is simply a potentially neurotoxic by-product of heme catabolism and emphasize the importance of understanding its potential beneficial physiologic and detrimental pathophysiologic effects, in order to appropriately consider bilirubin test results within the clinical laboratory setting. With this information, we hope to improve the understanding of disorders of bilirubin metabolism, emphasize the diagnostic importance of these conditions, and outline the potential impact GS may have on resistance to disease.

Entities:  

Keywords:  Crigler-Najjar syndrome; Gilbert´s syndrome; UGT1A1; bilirubin; diagnosis; hyperbilirubinemia

Mesh:

Substances:

Year:  2018        PMID: 29390925     DOI: 10.1080/10408363.2018.1428526

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  19 in total

1.  When Do Clinicians Follow-up Abnormal Liver Tests in Primary Care?

Authors:  Andrew D Schreiner; John Bian; Jingwen Zhang; Elizabeth B Kirkland; Marc E Heincelman; Samuel O Schumann; Patrick D Mauldin; William P Moran; Don C Rockey
Journal:  Am J Med Sci       Date:  2019-04-20       Impact factor: 2.378

2.  [A case of Gilbert syndrome caused by UGT1A1 gene compound heterozygous mutations].

Authors:  Weijie Ou; Su Lin; Yilong Wu; Yueyong Zhu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

3.  Gilbert's Syndrome, Bilirubin Level and UGT1A1∗28 Genotype in Men of North-West Region of Russia.

Authors:  Andrei Ivanov; Elena Semenova
Journal:  J Clin Exp Hepatol       Date:  2021-02-04

4.  The Association between Serum Bilirubin Levels and Colorectal Cancer Risk: Results from the Prospective Cooperative Health Research in the Region of Augsburg (KORA) Study in Germany.

Authors:  Nazlisadat Seyed Khoei; Gabriele Anton; Annette Peters; Heinz Freisling; Karl-Heinz Wagner
Journal:  Antioxidants (Basel)       Date:  2020-09-24

5.  UGT1A1-related Bilirubin Encephalopathy/Kernicterus in Adults.

Authors:  Jie Bai; Lu Li; Hui Liu; Shuang Liu; Li Bai; Wenyan Song; Yu Chen; Sujun Zheng; Zhongping Duan
Journal:  J Clin Transl Hepatol       Date:  2021-03-11

6.  Combined Effects of UGT1A1 and SLCO1B1 Variants on Chinese Adult Mild Unconjugated Hyperbilirubinemia.

Authors:  Jie Bai; Lei Luo; Shuang Liu; Chen Liang; Li Bai; Yu Chen; Sujun Zheng; Zhongping Duan
Journal:  Front Genet       Date:  2019-10-31       Impact factor: 4.599

7.  Inhibition of Lipid Accumulation in Skeletal Muscle and Liver Cells: A Protective Mechanism of Bilirubin Against Diabetes Mellitus Type 2.

Authors:  Claudia A Hana; Eva-Maria Klebermass; Theresa Balber; Markus Mitterhauser; Ruth Quint; Yvonne Hirtl; Antonia Klimpke; Sophie Somloi; Juliana Hutz; Elisabeth Sperr; Paulina Eder; Jana Jašprová; Petra Valášková; Libor Vítek; Elke Heiss; Karl-Heinz Wagner
Journal:  Front Pharmacol       Date:  2021-01-25       Impact factor: 5.810

8.  Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses.

Authors:  Nazlisadat Seyed Khoei; Mazda Jenab; Neil Murphy; Barbara L Banbury; Robert Carreras-Torres; Vivian Viallon; Tilman Kühn; Bas Bueno-de-Mesquita; Krasimira Aleksandrova; Amanda J Cross; Elisabete Weiderpass; Magdalena Stepien; Andrew Bulmer; Anne Tjønneland; Marie-Christine Boutron-Ruault; Gianluca Severi; Franck Carbonnel; Verena Katzke; Heiner Boeing; Manuela M Bergmann; Antonia Trichopoulou; Anna Karakatsani; Georgia Martimianaki; Domenico Palli; Giovanna Tagliabue; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; Guri Skeie; Susana Merino; Catalina Bonet; Miguel Rodríguez-Barranco; Leire Gil; Maria-Dolores Chirlaque; Eva Ardanaz; Robin Myte; Johan Hultdin; Aurora Perez-Cornago; Dagfinn Aune; Konstantinos K Tsilidis; Demetrius Albanes; John A Baron; Sonja I Berndt; Stéphane Bézieau; Hermann Brenner; Peter T Campbell; Graham Casey; Andrew T Chan; Jenny Chang-Claude; Stephen J Chanock; Michelle Cotterchio; Steven Gallinger; Stephen B Gruber; Robert W Haile; Jochen Hampe; Michael Hoffmeister; John L Hopper; Li Hsu; Jeroen R Huyghe; Mark A Jenkins; Amit D Joshi; Ellen Kampman; Susanna C Larsson; Loic Le Marchand; Christopher I Li; Li Li; Annika Lindblom; Noralane M Lindor; Vicente Martín; Victor Moreno; Polly A Newcomb; Kenneth Offit; Shuji Ogino; Patrick S Parfrey; Paul D P Pharoah; Gad Rennert; Lori C Sakoda; Clemens Schafmayer; Stephanie L Schmit; Robert E Schoen; Martha L Slattery; Stephen N Thibodeau; Cornelia M Ulrich; Franzel J B van Duijnhoven; Korbinian Weigl; Stephanie J Weinstein; Emily White; Alicja Wolk; Michael O Woods; Anna H Wu; Xuehong Zhang; Pietro Ferrari; Gabriele Anton; Annette Peters; Ulrike Peters; Marc J Gunter; Karl-Heinz Wagner; Heinz Freisling
Journal:  BMC Med       Date:  2020-09-03       Impact factor: 8.775

9.  UGT1A1 Variants c.864+5G>T and c.996+2_996+5del of a Crigler-Najjar Patient Induce Aberrant Splicing in Minigene Assays.

Authors:  Linda Gailite; Alberto Valenzuela-Palomo; Lara Sanoguera-Miralles; Dmitrijs Rots; Madara Kreile; Eladio A Velasco
Journal:  Front Genet       Date:  2020-03-06       Impact factor: 4.599

10.  Carbon monoxide breath test assessment of mild hemolysis in Gilbert's syndrome.

Authors:  Ling-Ling Kang; Yong-Jian Ma; Hou-De Zhang
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.